Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: A systematic review and meta-analysis

Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Robert T. Williams; Martin S. Tallman; Amer M. Zeidan; Maximilian Stahl

doi:10.3324/HAEMATOL.2019.242826

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: A systematic review and meta-analysis

Jan Philipp Bewersdorf, Smith Giri, Rong Wang, Robert T. Williams, Martin S. Tallman, Amer M. Zeidan, Maximilian Stahl^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

74 Scopus citations

Original language	English (US)
Journal	Haematologica
Volume	105
Issue number	5
DOIs	https://doi.org/10.3324/HAEMATOL.2019.242826
State	Published - Jan 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/HAEMATOL.2019.242826

Cite this

Bewersdorf, J. P., Giri, S., Wang, R., Williams, R. T., Tallman, M. S., Zeidan, A. M., & Stahl, M. (2020). Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: A systematic review and meta-analysis. Haematologica, 105(5). https://doi.org/10.3324/HAEMATOL.2019.242826

@article{7175530535724fdcbe8fd42445c205d7,

title = "Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: A systematic review and meta-analysis",

author = "Bewersdorf, {Jan Philipp} and Smith Giri and Rong Wang and Williams, {Robert T.} and Tallman, {Martin S.} and Zeidan, {Amer M.} and Maximilian Stahl",

note = "Funding Information: publication was supported by the NCI of the National Institutes of Health under Award Funding Information: Amer Zeidan is a Leukemia and Lymphoma Society Scholar in Clinical Research and is also supported by a National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award (CCITLA). Research reported in this publication was supported by the NCI of the National Institutes of Health under Award Number P30 CA016359. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: received research funding from Abbvie, Cellerant, Orsenix, ADC Therapeutics, and Funding Information: Clinical Research and is also supported by a National Cancer Institute (NCI) Cancer",

year = "2020",

month = jan,

doi = "10.3324/HAEMATOL.2019.242826",

language = "English (US)",

volume = "105",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "5",

}

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: A systematic review and meta-analysis. / Bewersdorf, Jan Philipp; Giri, Smith; Wang, Rong et al.
In: Haematologica, Vol. 105, No. 5, 01.2020.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia

T2 - A systematic review and meta-analysis

AU - Bewersdorf, Jan Philipp

AU - Giri, Smith

AU - Wang, Rong

AU - Williams, Robert T.

AU - Tallman, Martin S.

AU - Zeidan, Amer M.

AU - Stahl, Maximilian

N1 - Funding Information: publication was supported by the NCI of the National Institutes of Health under Award Funding Information: Amer Zeidan is a Leukemia and Lymphoma Society Scholar in Clinical Research and is also supported by a National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award (CCITLA). Research reported in this publication was supported by the NCI of the National Institutes of Health under Award Number P30 CA016359. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: received research funding from Abbvie, Cellerant, Orsenix, ADC Therapeutics, and Funding Information: Clinical Research and is also supported by a National Cancer Institute (NCI) Cancer

PY - 2020/1

Y1 - 2020/1

UR - http://www.scopus.com/inward/record.url?scp=85085000743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085000743&partnerID=8YFLogxK

U2 - 10.3324/HAEMATOL.2019.242826

DO - 10.3324/HAEMATOL.2019.242826

M3 - Review article

C2 - 33131256

AN - SCOPUS:85085000743

SN - 0390-6078

VL - 105

JO - Haematologica

JF - Haematologica

IS - 5

ER -

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: A systematic review and meta-analysis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this